Global Human Rotavirus Vaccine Market According to Data Bridge Market Research new Market report, “By Type (Rotarix, Rotavac, Rotavin-M1, Lanzhou Lamb, Others), By End User (Hospitals, Clinics, Academic & Research Lab), Byy Distribution Channel (Hospital Pharmacies, Drug Stores), By Geography (North America, Europe, Asia-Pacific, South America, Middle East & Africa) - Industry Trends and Forecast is projected to reach USD 16.63 billion by 2025, at a CAGR of 11.7% during the forecast period of 2018 to 2025.
Global Human Rotavirus Vaccine Market
Rotavirus is a virus which infects the bowels and causes severe inflammation of the stomach and gastroenteritis. The rotavirus disease is one of the most common diseases amongst infants and young children. Rare cases of older children and adults got sick through rotavirus have been reported. The rotavirus has been the most common cause of severe diarrhea among infants and children worldwide.
According to Centers for Disease Control and Prevention (CDC), previously the rotavirus disease was serious health problem for children in the U.S., amongst all children in U.S. had at least one rotavirus infection before the age of 5. The same article reports that prior the availability of vaccine more than 4,00,000 young children visited doctors for illness caused by rotavirus and more than 2,00,000 had moved to emergency room. It also reported that 55,000 to 70,000 had been hospitalized and 20 to 60 died.
The global market for human rotavirus vaccine by the following sub-categories is presented
FACTORS DRIVING GROWTH IN THE GLOBAL HUMAN ROTAVIRUS VACCINE MARKET
Increasing prevalence of rotavirus diseases:
Rotavirus has been the leading cause of severe diarrhea in infants and children. Rotaviruses are responsible to affect the populations in all socioeconomic groups and it is prevalent in industrialized as well as in developing countries. The rotavirus infection is highly transmittable and the people who are around the infected people are at high risk of infection.
The World Health organization (WHO), in 2016 estimated that globally 2,15,000 (1,97,000-2,33,000) child deaths occurred during 2013 due to rotavirus infection compared to 5,28,000 (4,65,000-5,91,000) in 2000. It also reported that 22.0% of deaths under 5 years of age occurred in India. Accompanied by India, Nigeria, Pakistan and the Democratic Republic of the Congo accounted approximately 49.0% of all deaths under the age of 5 in 2013.
As rotavirus infection has been the most common cause of severe diarrhea, many national authorities has taken initiatives to launch rotavirus vaccines in the market. India is one of the most affected countries by rotavirus. It is been studied that in India, rotavirus diarrhea causes 110,000 deaths amongst the annual over 450,000 deaths worldwide.
In India, in March 2015 Hon’ble Prime Minister Narendra Modi launched rotavirus vaccine Rotavac, developed by Hyderabad-based Bharat Biotech. In 2017, the Serum Institute of India Pvt. Ltd. revealed the result of clinical trial Phase 3 efficacy study of rotavirus vaccine BRV-PV, ROTASIIL. The study has showed that vaccine is safe, well tolerated, and to provide significant efficacy against severe rotavirus gastroenteritis. And therefore, Indian Government orders the vaccine for use in Universal Immunization Program.
Growing focus of market players
The global human rotavirus vaccine market report contains an in-depth profiling of the key market players, along with the recent developments (new product launches, partnerships, agreements, collaborations, and joint ventures) and strategies adopted by them to sustain and strengthen their position in the market. The report also covers the market shares for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America market.
Some of the major players operating in global human rotavirus vaccine market include Bharat Biotech, Merck & Co., Inc., GlaxoSmithKline plc among others.
Browse Related Reports:
Global Human Insulin Drugs and Delivery Devices Market, By Product Type, By End-User, By Distribution Channel, By Geography (North America, South America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA)) – Industry Trends and Forecast to 2024
Europe Fetal Bovine Serum Market, By Product type, By End-User, By Distribution Channel, By Country (Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest Of Europe) – Industry Trends and Forecast to 2024
Global Vaccine Adjuvants Market, Product Type (Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants, Liposome Adjuvants, Carbohydrate Adjuvants, Alum, Others), Category (Human Vaccine Adjuvants, Veterinary Vaccine Adjuvants), Route of Administration, Disease Type, Application, Mechanism of Action, Geography- Industry Trends and Forecast to 2024
Global Pediatric Vaccine Market, By Product (pediatric vaccines, CNS drugs, pediatric hormones, allergy & respiratory drugs and anti-infective drugs); By Technology (dendritic cells vaccines, live attenuated vaccines, synthetic vaccines, toxoid vaccines, inactivated vaccines, conjugate vaccines, recombinant vector vaccines and subunit vaccines); By Disease (Infectious disease, cancer and allergy); End-Users (Pediatric, Adult); Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa)- Industry Trends and Forecast to 2024
Global Human Rotavirus Vaccine Market - Industry Trends and Forecast to 2026